Jack Henry & Associates, Inc. (0A6D)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 161.26 |
|---|---|
| 52-week range | 121.51 – 194.33 |
| Return, 1 month / 3 months | +7.6% / +7.1% |
| Return, 1 year / 3 years | +3.7% / +16.7% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 32.3% |
| Worst drawdown (1 year) | -35.2% |
| Average daily value traded | 0.02M USD |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Jack Henry & Associates supplies technology systems and services to community and regional banks and credit unions, mainly in the United States. Its core processing platforms run deposit, loan and customer account records, and it also offers payments processing, digital banking, card services, lending software and related support. The company is based in Monett, Missouri, and serves financial institutions that range from small community banks to larger regional organisations.
Jack Henry & Associates, Inc. trades under the code 0A6D on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Jack Henry & Associates, Inc. (0A6D) trades on the London Exchange in UK. It last closed at USD 161.26 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,220 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.7% and over the last three months it rose 7.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 55 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.8% | ||
| From 52-week high | -15.9% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.1% | ||
| 6-month return | 5.0% | ||
| 12-month return, skipping the last month | -3.6% | ||
| Stability (higher is calmer) | 48 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.2% | ||
| Liquidity | 12 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M USD | ||
| Zero-volume days | 40.0% | ||
| Income | 54 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.6% |
|---|---|
| 1 month | +7.6% |
| 3 months | +7.1% |
| 6 months | +5.0% |
| 1 year | +3.7% |
| 3 years | +16.7% |
| 5 years | −1.0% |
Signals
| 50-day / 200-day average | 152.04 / 152.48 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.87 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Sep 2026 | USD 0.6100 |
| 1 Jun 2026 | USD 0.6100 |
| 5 Mar 2026 | USD 0.6100 |
| 2 Dec 2025 | USD 0.5800 |
| 5 Sep 2025 | USD 0.5800 |
| 29 May 2025 | USD 0.5800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.